Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2019 Aug 19;34(1):296–300. doi: 10.1038/s41375-019-0533-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Progression-free survival in patients with successful karyotyping in the idelalisib arm. b Overall survival in patients with successful karyotyping. c Forest plot of hazard ratios for OS by prespecified subgroups and the presence or absence of complex karyotype in the idelalisib arm. CI confidence interval, CK complex karyotype, HR hazard ratio, IDELA idelalisib, IGHV immunoglobulin heavy-chain variable region gene, LCL lower confidence limit, no CK no complex karyotype, NR not reached, OS overall survival, PBO placebo, PFS progression-free survival, R rituximab, UCL upper confidence limit